MedPath

PHILOS Augmented - a Multicenter Randomized Controlled Trial

Not Applicable
Completed
Conditions
Humerus Fractures
Closed Fracture of the Proximal Humerus
Interventions
Device: PHILOS+
Device: PHILOS
Registration Number
NCT01847508
Lead Sponsor
AO Clinical Investigation and Publishing Documentation
Brief Summary

The primary objective is to compare the mechanical failure risks in the first year after treatment.

Detailed Description

Biomechanical tests have shown that augmentation of screws or nails with polymethylmethacrylate (PMMA) leads to increased mechanical properties of the bone-implant complex, leading to the assumption that augmentation could reduce mechanical failures in patients. While a few clinical studies have already been performed with augmented trochanteric nails in proximal femur fractures, no clinical studies exist with the use of Proximal Humerus Internal Locking System (PHILOS) and (PMMA) augmentation for the treatment of fractures in the proximal humerus.

In this study a new standardized technique for augmentation of screw tips using high viscous PMMA cement (Traumacem V+) with the PHILOS plate will be applied. Fracture treatment with PHILOS Screw Augmentation will be compared with treatment with PHILOS without augmentation.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
69
Inclusion Criteria
  • Age ≥ 65 years
  • Low energy trauma (e.g. fall from standing height)
  • Radiologically confirmed closed fracture (≤ 10 days) of the proximal humerus
  • Any displaced or unstable 3- or 4-part fracture of the proximal humerus (i.e. segment dis-placement > 0.5 cm or angulated > 45°) except isolated displaced fractures of the greater or lesser tuberosity
  • Primary fracture treatment with a PHILOS plate
  • Ability to understand the content of the patient information / informed consent form
  • Willingness and ability to participate in the clinical investigation including imaging and fol-low-up procedures
  • Signed informed consent

Preoperative

Exclusion Criteria
  • Bilateral or previous proximal humerus fractures on either side
  • Splitting fracture of the humeral head or humeral head impression fracture
  • Cuff-arthropathy of the contra- or ipsilateral proximal humerus
  • Associated nerve or vessel injury
  • Any known clotting disorders, severe cardiac and/or pulmonary insufficiency
  • Known hypersensitivity or allergy to any of the components of Traumacem V+ Cement Kit
  • Any severe systemic disease: class 4 - 6 of the American Society of Anesthesiologists (ASA) physical status classification
  • Any not medically managed severe systemic disease: class 3 of the ASA physical status classification
  • Recent history of substance abuse (i.e. recreational drugs, alcohol) that would preclude reliable assessment
  • Prisoner
  • Participation in any other medical device or medicinal product study within the previous month that could influence the results of the present study

Intraoperative Exclusion Criteria:

  • Intraoperative decision to use implants other than PHILOS/PHILOS Screw Augmentation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PHILOS +PHILOS+Proximal Humeral Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
PHILOSPHILOSProximal Humeral Internal Locking System (PHILOS)
Primary Outcome Measures
NameTimeMethod
Any occurrence of radiographically confirmed mechanical failure during the first year after treatment.one year

Mechanical failures are defined as loss of reduction (≥ 15° increase of varus malposition between the immediate postoperative position and follow-up radiograph, relative change \[5 mm\] of greater or lesser tuberosity compared to the immediate postoperative position), head impaction (≥ 5 mm difference in outer plate edge and tangent of humeral head between immediate post-op and follow-up. The tangent is determined perpendicular to the humeral neck), screw/plate loosening (any change outwards of screw position in relation to immediate postoperative position) and secondary screw perforation (perforation of one or more screws through the humeral head into the joint space on the follow-up radiograph(and lack of screw perforation on the intra- or postoperative Rx based on a baseline anteroposterior and axial Rx.

Secondary Outcome Measures
NameTimeMethod
Reoperation rateUp to one year
Shoulder functionPreoperative, 6 weeks ±7 days, 12 weeks ± 14 days, 6 months ± 30 days, 12 months up to 425 days after surgery

Disabilities of the Arm, Shoulder and Hand Score (QuickDASH).

Relation of patient factors on mechanical failuresUp to one year

Bone mineral density (BMD) measured with CT.

Relation of surgical factors on mechanical failuresUp to one year

Time of surgery.

Intra- and postoperative adverse events related to the procedure and/or deviceUp to one year

Implant/surgery , Bone/fracture, Soft tissue of the musculoskeletal system, Wound/other local tissue, Systemic/rest of the body.

Relation of fracture characteristics on mechanical failuresUp to one year

Varus/valgus.

Patient reported outcome (Quality of life)Preoperative, 6 weeks ±7 days, 12 weeks ± 14 days, 6 months ± 30 days, 12 months up to 425 days after surgery

EuroQol-5D (EQ-5D).

Description of augmentation detailsIntraoperative

Volume of injected cement (in ml).

Surgical detailsIntra- /postoperative

Restoration of medial support.

Trial Locations

Locations (9)

UZ Leuven

🇧🇪

Leuven, Belgium

Medical University of Innsbruck

🇦🇹

Innsbruck, Austria

BG Clinic Ludwigshafen

🇩🇪

Ludwigshafen, Germany

University Medical Center Freiburg

🇩🇪

Freiburg, Germany

University Hospital RWTH Aachen

🇩🇪

Aachen, Germany

Saarland University Medical Center

🇩🇪

Homburg, Germany

BG Clinic Tübingen

🇩🇪

Tübingen, Germany

Triemli hospital

🇨🇭

Zürich, Switzerland

Cantonal Hospital Lucerne

🇨🇭

Lucerne, Switzerland

© Copyright 2025. All Rights Reserved by MedPath